Prosecution Insights
Last updated: November 04, 2026
Application No. 17/049,623

Process for the Production of Tetrazolinones

Final Rejection §103
Filed
Oct 22, 2020
Priority
Apr 25, 2018 — EU 18169142.9 +1 more
Examiner
MAHLUM, JONATHAN DAVIS
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Dynamit Nobel GmbH Explosivstoff-Und Systemtechnik
OA Round
5 (Final)
48%
Grant Probability
Moderate
6-7
OA Rounds
0m
Est. Remaining
74%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allowance Rate
21 granted / 44 resolved
-12.3% vs TC avg
Strong +26% interview lift
Without
With
+26.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
49 currently pending
Career history
104
Total Applications
across all art units

Statute-Specific Performance

§101
2.4%
-37.6% vs TC avg
§103
35.7%
-4.3% vs TC avg
§102
18.0%
-22.0% vs TC avg
§112
25.7%
-14.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 44 resolved cases

Office Action

§103
Detailed Action The present office action is in response to the request for continued examination filed on 14 Apr 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 14 Apr 2026 has been entered. Status Claims 1-8, 10-16, and 18-20 of the pending application have been examined on the merits. Acknowledgement is made of the amendments filed 06 Aug 2025. Acknowledgement is made of the cancellation of claims 9 and 17. Priority The instant application retains the priority date of 25 Apr 2018. Response to Arguments Acknowledgement is made of the remarks filed 14 Apr 2026. The non-statutory double patenting rejections over copending Application Nos. 17/047,671 and 17/766,286 are rendered moot following abandonment of the copending applications. Regarding the rejection of claims 1-8, 10-16, and 18-20 under 35 U.S.C. § 103, applicant arguments filed 14 Apr 2026 have been fully considered but are not persuasive. Claims 1-8, 10-16, and 18-20 stand rejected under 35 U.S.C. § 103 over JP 2016113426 (provided in IDS 11/22/23), hereinafter ‘426, further in view of Vorbruggen et al. (Synthesis, 1979, 1:35; provided in the office action mailed 20 Feb 2025), hereinafter Vorbruggen, Xu et al. (Synthetic Comm, 2006, 37:3095-3104; abstract provided in the office action mailed 20 Feb 2025), hereinafter Xu, and Cantillo et al. (J Am Chem Soc, 2011, 133:4465-4475; provided in the office action mailed 20 Feb 2025), hereinafter Cantillo. Applicant argues in the remarks filed 14 Apr 2026 that the purpose and chemical context of Vorbruggen, Cantillo, and Xu significantly differ from the context of ‘426. Applicant argues that Vorbruggen discloses several products formed through the use of the in situ generated TMSN3, but that Vorbruggen is entirely silent about the formation of tetrazolinones via the use of in situ generated TMSN3. Because the functional groups of Vorbruggen differ from those in ‘426, applicant argues that the substrates having different functional groups would behave differently (pg. 6-7). Examiner respectfully notes that Vorbruggen is used to teaches the in situ generation of TMSN3 from reacting TMSCl and NaN3. The method for preparing compound 6 of Vorbruggen requires adding TMSCl to NaN3 in DMF and stirring for an hour prior to any other reagents being added (column 2). The relevance of Vorbruggen is maintained. See MPEP § 2141.01(a)(I). Applicant argues that Cantillo's teachings that stoichiometric amounts of expensive TMSN3 can be replaced by stoichiometric amounts of inexpensive NaN3 and catalytic amounts of TMSN3 or TMSCl corresponds to a specific catalysis condition and that the purpose and chemical context of Cantillo significantly differ from those of '426 (pgs. 6-7). Cantillo is cited for disclosing the use of catalytic amounts of TMSN3 or TMSCl and stoichiometric amounts of NaN3 to afford TMSN3 in a cyclization reaction, corroborating Vorbruggen and showing that TMSN3 can be generated by catalytic amounts of TMSCl and NaN3 which applies directly to the reaction taught by ‘426 where the azidizing reagent is sodium azide or TMSN3. See MPEP § 2141.01(a)(I). Applicant argues that an artisan would understand that the teaching is not directly applicable to the subject matter of '426 because Xu relates to specific Michael-type Friedel-Crafts reactions separate from the disclosure of '426 (pgs. 7-8). Applicant further argues that while TMSCl may be classified as a Lewis acid, the artisan would understand this is chemically distinct than the Lewis acids cited in the disclosure of '426 (pg. 8), the reasoning being that TMSCl reacts with NaN3 to form neutral, covalent bonds while the Lewis acids described in ‘426 react with NaN3 to form intermediates which remain Lewis acids. The relevance of Xu relates to Xu teaching that TMSCl is a Lewis acid. The relevance of Xu is maintained and it is respectfully requested that applicant provide evidence for the arguments that the Lewis acids described in ‘426 are distinct enough that the artisan would not have a reasonable expectation of success in using TMSCl as a Lewis acid in the reaction. See MPEP § 2141.01(a)(I) and MPEP § 2145(I). Applicant further argues that Vorbruggen does not disclose the use of such TMSN3 in a catalytic amount (pg. 8). This is not persuasive because the use of TMSN3 in a catalytic amount is gleaned from disclosures of '426, Vorbruggen, Cantillo, and Xu. Vorbruggen is cited for teaching the in situ generation of TMSN3 by reacting TMSCl and NaN3. Examiner notes that attacking references individually cannot be used to show nonobviousness. See MPEP § 2145(IV). Applicant argues that there is no stoichiometric amount of TMSN3 in ‘426 that is to be replaced by NaN3 and a catalytic amount of TMSN3 or TMSCl, and that further TMSCl is a Lewis acid taught by Xu and not TMSN3. Applicant further argues that no document of record teaches a compound of formula (II) to be a Lewis acid catalyst (pg. 8), and that the obviousness rejection is based on hindsight bias. Examiner respectfully reiterates that ‘426 teaches the addition of a 0.01-0.5 molar equivalents of a Lewis acid to the reaction which may include NaN3 or TMSN3 as the azidizing reagent. Xu teaches TMSCl is a Lewis acid and Vorbruggen and Cantillo teach that TMSCl and NaN3 react in situ to form TMSN3. Together the references make the presently claimed invention obvious to a person having ordinary skill in the art (see “Claim Rejections – 35 USC § 103” below). In response to applicant’s argument that the examiner’s conclusion of obviousness is based on improper hindsight reasoning, it must be recognized that any judgement on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill before the time of the claimed invention’s effective filing date, and does not include knowledge gleaned only from the applicant’s disclosure, such a reconstruction is proper. See MPEP § 2145(X). Applicant argues that the claimed molar range of ‘426 is limited to the specific metal chloride Lewis acids described in the reference disclosure. Applicant specifically relies on paragraph [0019] of ‘426 which states, “If necessary, Lewis acids such as aluminum chloride, titanium tetrachloride, or zinc chloride may be added to the reaction; aluminum chloride is preferably used. These Lewis acids are typically used in amount of 0.001 to 1 mole, preferably 0.01 to 0.5 mole, per mole of compound (5).” Applicant interprets the word “these” of the phrase “These Lewis acids” to limit the list of Lewis acids to only those explicitly mentioned in ‘426. Applicant reiterates the argument that the Lewis acids of ‘426 are chemically distinct from TMSCl as a Lewis acid (pg. 10). This is not persuasive. Paragraph [0019] still makes sense if all exemplary statements are removed. “If necessary, Lewis acids…may be added to the reaction. These Lewis acids are typically used in amount of 0.001 to 1 mole…per mole of compound (5).” Evidence is required to substantiate the applicant arguments. See MPEP § 2145(I). In light of the discussion above, the rejection of claims 1-8, 10-16, and 18-20 is under 35 U.S.C. § 103, as obvious over ‘426, Vorbruggen, Cantillo, and Xu is maintained for the reasons of record and restated below. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-8, 10-11, 15-16, and 18-19 is/are rejected under 35 U.S.C. 103 as being unpatentable over '426, and further in view of Vorbruggen, Xu, and Cantillo. '426 teaches a method for making a tetrazolinone (pg. 4, Compound 6) from an isocyanate (pg. 4, Compound 5): PNG media_image1.png 73 145 media_image1.png Greyscale PNG media_image2.png 102 150 media_image2.png Greyscale '426 teaches using an azidizing agent to cyclize Compound 5 normally carried out in a solvent, where the possible solvents include N,N-dimethylformamide and N-methylpyrrolidone (pg. 8, paragraph [0019]). '426 additionally teaches the azidizing agents may compounds which include sodium azide or TMSN3 (pg. 8, paragraph [0019]). '426 teaches that a Lewis acid may be added to the reaction, used in a preferable amount of 0.01 to 0.5 moles relative to moles of Compound 5. '426 further teaches that when the solvent, the Lewis acid, and the azidation agent are mixed and then Compound 5 is added, the temperature at which the Lewis acid and the azidation agent are mixed is usually in the range of -20 to 100 °C. However, '426 does not teach the Lewis acid as a silicon derivative or making the silicon derivative in situ. Vorbruggen teaches the use of trimethylsilyl azide as a reagent does not require its separate preparation prior to the reaction with substrates such as aldehydes, ketones, or isothiocyanates and that it may be generated in situ from trimethylchlorosilane and sodium azide (pg. 35, column 1). Xu teaches that trimethylchlorosilane is an effective silicon Lewis acid catalyst (Abstract, lines 1-2). Cantillo teaches that stoichiometric amounts of the expensive TMSN3 can be replaced by stoichiometric amounts of inexpensive NaN3 and catalytic amounts of TMSN3 or even TMSCl which readily affords TMSN3 in the presence of the azide ion (pg. 4470, column 1). It would be obvious to one having ordinary skill in the art to combine the teachings of '426, Vorbruggen, Xu, and Cantillo to create Compound 6 from Compound 5 by creating the azidizing reagent TMSA in situ from catalytic amounts of the Lewis acid, TMSCl, and azidizing reagent, NaN3, all while reacting in a solvent of DMA or NMP at a temperature between -20 and 100 °C. A person having ordinary skill in the art would be motivated to form TMSA in situ using catalytic amounts of TMSCl and stoichiometric amounts of NaN3 because stoichiometric TMSA is an expensive reagent and replacing stoichiometric TMSA with catalytic TMSCl and cheap NaN3 would reduce costs. Additionally, the artisan would be motivated to form TMSA in situ due to the added convenience generated by forming reagents in situ. Furthermore, the selection of a reaction temperature is a result effective variable that would have been routinely determined and optimized in the pharmaceutical art, as exemplified by ‘426 which teaches a widely variable reaction temperature of -20 °C to 100 °C. It is noted that no criticality has been demonstrated in the instant specification with regard to the claimed reaction temperatures. To summarize the teachings above: Vorbruggen and Cantillo teach NaN3 reacts with catalytic amounts of TMSCl to form TMSA in situ which read on instant claims 1-2, 4-8, and 16. '426 teaches DMF and NMP are amide solvents which reads on instant claims 1, 3, and 15. '426 and Xu teach using 0.01-0.5 molar equivalents of the Lewis acid, TMSCl, which reads on instant claims 9 and 18. '426 teaches Compound 5 as an aryl isocyanate and Compound 6 as an aryl tetrazolinone which reads on instant claim 10. '426 teaches a reaction temperature between -20 and 100 °C which reads on instant claims 11 and 19. A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (In re Opprecht 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); In re Bode 193 USPQ 12 (CCPA) 1976). In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Claim(s) 1-8, 10-16, and 18-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over '426, Vorbruggen, Xu, and Cantillo as applied to claims 1-8, 10-11, 15-16, and 18-19 above. '426, Vorbruggen, Xu, and Cantillo teach a method of preparing Compound 6 (above) by reacting 0.01 to 0.5 molar equivalents of TMSCl with NaN3 to create TMSA which in turn reacts with Compound 5 to create Compound 6. This reaction is performed in a solvent, preferably DMF, at a temperature between -20 °C and 100 °C. '426 also teaches that after performing a reaction to create Compound 6, the mixture can be cooled, with a mixture of sodium nitrite and hydrochloric acid added dropwise (pg. 13, paragraph [0027]. ‘426 teaches the reaction was cooled and hydrochloric acid was added, after which water was added to the mixture followed by cooling and filtering (pg. 13, paragraph [0027]). ‘426 also teaches that sodium nitrite is an oxidizing agent that decomposes excess azidation agent (pg. 8, paragraph [0019]). ‘426 teaches that excess azidation agent may also be removed and Compound 6 isolated by performing post-treatment operations such as washing, extraction, concentration, filtration, and drying. However, '426 does not teach the steps of purifying the tetrazolinone compound prior to treating with NaNO2 and acid. It would be prima facie obvious to one having ordinary skill in the art to try variations of washing, extraction, concentration, filtration, drying, and treating with NaNO2 and acid to ensure that any excess azidation reagent is removed. For instance, while ‘426 teaches treating the reaction to form Compound 6 with NaNO2 and acid followed by isolation of Compound 6 by filtration, an artisan would find it obvious to try filtering Compound 6 followed by treating with NaNO2 and acid in order to determine the best order of operations for removing excess azidation reagent. Furthermore, the artisan would be motivated to try different isolation and purification methods to ensure the highest possible yield of Compound 6. To summarize the teachings above: ‘426 and ‘339 teach a method of first isolating a tetrazolinone compound following by treating the compound with NaNO2 and HCl which reads on claims 12-14 and 20. A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (In re Opprecht 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); In re Bode 193 USPQ 12 (CCPA) 1976). In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Conclusion No claim is allowed. All claims are identical to or patentably indistinct from, or have unity of invention with claims in the application prior to the entry of the submission under 37 CFR 1.114 (that is, restriction (including a lack of unity of invention) would not be proper) and all claims could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jonathan D. Mahlum whose telephone number is (703)756-4691. The examiner can normally be reached 8:30 AM - 5:00 PM ET, M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.D.M./Examiner, Art Unit 1625 /Andrew D Kosar/Supervisory Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Show 4 earlier events
Jun 24, 2024
Request for Continued Examination
Jun 28, 2024
Response after Non-Final Action
Feb 20, 2025
Non-Final Rejection mailed — §103
Aug 06, 2025
Response Filed
Dec 29, 2025
Final Rejection mailed — §103
Apr 14, 2026
Request for Continued Examination
Apr 18, 2026
Response after Non-Final Action
Oct 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12759982
ARYL OR HETEROARYL DERIVATIVE
4y 0m to grant Granted Oct 13, 2026
Patent 12723036
ARYLTETRAHYDROPYRIDAZINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF
3y 8m to grant Granted Sep 01, 2026
Patent 12723032
METHOD FOR PRODUCING URACIL COMPOUND
2y 7m to grant Granted Sep 01, 2026
Patent 12686689
HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
3y 11m to grant Granted Jul 21, 2026
Patent 12686691
CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
3y 7m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
48%
Grant Probability
74%
With Interview (+26.0%)
3y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 44 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month